Association between serum ferritin and glycated hemoglobin in patients with type 2 diabetes mellitus in a hospital in Lima, Peru, 2023.

Read full text Summarise with VIRAT
Authors: Lisset Maribel Rojas Banda
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

🔹 ABSTRACT Background: Serum ferritin, in addition to reflecting iron stores, has been linked to inflammatory processes and metabolic alterations in patients with type 2 diabetes mellitus. However, its association with glycemic control in the Peruvian population is not clearly established. Objective: To determine the association between serum ferritin levels and glycated hemoglobin in patients with type 2 diabetes mellitus at a hospital in Lima, Peru. Methods: This was an observational, analytical, cross-sectional study that included 164 patients with type 2 diabetes mellitus. Patients with elevated and normal ferritin levels were compared. Descriptive statistics, the chi-square test, and relative risk (RR) calculation were used, considering p < 0.05 as statistically significant. Results: 50% of the patients presented with elevated ferritin and 61.6% had glycated hemoglobin greater than 7%. 74.4% of patients with elevated ferritin levels had poor glycemic control, compared to 48.8% in the group with normal ferritin levels (p=0.003). Patients with elevated ferritin levels had a higher risk of poor glycemic control (RR=1.52; 95% CI: 1.15–2.01). Conclusions: There is a significant association between elevated ferritin and poor glycemic control in patients with type 2 diabetes mellitus, suggesting its usefulness as a complementary biomarker in metabolic assessment. Keywords: Type 2 diabetes mellitus, ferritin, glycated hemoglobin, glycemic control, biomarkers.

Fields of Study & Subjects

Iron Metabolism and Disorders Diabetes Management and Research Adipokines Inflammation and Metabolic Diseases

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
25 March 2026
Language
EN